JCR Pharmaceuticals (4552) Fundamentals 2026 — P/E 29.2x, Revenue Analysis | SniperIQ
JCR Pharmaceuticals (4552) is a JP-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥63.7B, trading at ¥522.00 on the JPX. This SniperIQ fundamentals page covers JCR Pharmaceuticals's valuation (P/E 29.2x, P/B 1.4x), profitability (net margin 5.4%), revenue (¥40.3B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JCR Pharmaceuticals's market cap?
JCR Pharmaceuticals (4552) has a market capitalization of approximately ¥63.7B, trading at ¥522.00 on the JPX. Market cap moves with the live share price.
What is JCR Pharmaceuticals's P/E ratio?
JCR Pharmaceuticals's trailing twelve-month P/E ratio is 29.2x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JCR Pharmaceuticals?
JCR Pharmaceuticals runs a net profit margin of 5.4%, a gross margin of 74.6%, and an operating margin of 1.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JCR Pharmaceuticals generate?
JCR Pharmaceuticals reported revenue of ¥40.3B for fiscal year 2026, with net income of ¥2.2B and earnings per share (EPS) of 17.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JCR Pharmaceuticals pay a dividend?
JCR Pharmaceuticals offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JCR Pharmaceuticals financially healthy?
JCR Pharmaceuticals carries a debt-to-equity ratio of 1.15x and a current ratio of 1.16x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JCR Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JCR Pharmaceuticals (4552) the key facts are: market cap ¥63.7B, P/E 29.2x, revenue ¥40.3B, 52-week range 444-824. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JCR Pharmaceuticals's full fundamentals live
Get JCR Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.